FcRn inhibitor demonstrates sustained IgG reduction in Phase I trial
Viridian Therapeutics has announced positive Phase I trial results for VRDN-008, a half-life extended bifunctional FcRn inhibitor licensed from Paragon Therapeutics.
In the trial, VRDN-008 demonstrated a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile with the potential to be dosed every eight weeks.
VRDN-008 demonstrated an extended half-life of 15–18 days, up to six times longer than the first-generation Fc fragments. It demonstrated deep and sustained IgG reduction through eight weeks after dosing in healthy volunteers, with 74% IgG reduction at peak.
VRDN-008 also demonstrated a safety profile that spared albumin and LDL and was generally well-tolerated, with no serious adverse events or dose-limiting toxicities in the trial.
“Today’s VRDN-008 data exceeded expectations and demonstrate a potentially transformative FcRn-inhibitor profile. Based on these data, we believe VRDN-008 dosed subcutaneously every eight weeks can deliver deep and sustained IgG reductions and could provide patients a potential best-in-class option for extended disease control and convenience. We view this as a major clinical advancement for patients living with autoantibody-mediated autoimmune diseases,” said Steve Mahoney, President and Chief Executive Officer of Viridian.
“We plan to advance VRDN-008 rapidly into registrational development starting with myasthenia gravis (MG) in mid-2027, pending feedback from regulatory authorities. Beyond MG, there are multiple autoantibody-mediated autoimmune diseases where we believe that we can develop VRDN-008, including several that are clinically validated for FcRn inhibition, each representing addressable multi-billion-dollar market opportunities.”
Subcutaneous administration of VRDN-008 is planned via Enable enFuse, a simple, wearable device that operates with a single push of a button. enFuse is currently in use with multiple FDA approved medicines and in development as a next-generation delivery system for multiple drugs, including a blockbuster market leader in multiple sclerosis.
